PhaseBio Pharmaceuticals (PHAS) Stock Price, News & Analysis

Company Overview

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 9.65 million shs
• Average Volume: 848,888 shs
• Market Capitalization: $3.50 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

PHAS Stock Analysis - Frequently Asked Questions

How were PhaseBio Pharmaceuticals' earnings last quarter?

PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) issued its earnings results on Wednesday, November, 10th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.59) by $0.07. The business earned $0.34 million during the quarter, compared to analyst estimates of $2.67 million.

When did PhaseBio Pharmaceuticals IPO?

PhaseBio Pharmaceuticals (PHAS) raised $66 million in an initial public offering on Thursday, October 18th 2018. The company issued 5,000,000 shares at a price of $12.50-$14.00 per share. Citigroup, Cowen and Stifel served as the underwriters for the IPO and Needham was co-manager.

What other stocks do shareholders of PhaseBio Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PhaseBio Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM), VBI Vaccines (VBIV), Outlook Therapeutics (OTLK), Viking Therapeutics (VKTX) and Anavex Life Sciences (AVXL).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 1/21/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PHAS
• CUSIP: N/A
• CIK: 1169245
• Web: www.phasebio.com
• Phone: (610) 981-6500
• Fax: N/A
• Employees: 60
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($2.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-131,070,000.00
• Net Margins: -12,572.13%
• Pretax Margin: -12,572.13%
• Return on Equity: N/A
• Return on Assets: -174.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.47
• Quick Ratio: 0.47

Sales & Book Value

• Annual Sales: $818,000.00
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.93) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 49,858,000
• Free Float: 44,922,000
• Market Cap: $3.50 million
• Optionable: Not Optionable
• Beta: 2.57